Meihua International Medical Technologies Co., Ltd.
MHUAF Healthcare Medical Instruments & Supplies
Meihua International Medical Technologies Co., Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $61.8 million, down 36.2% from fiscal 2024.
Follow MHUAF
Meihua International Medical Technologies Co., Ltd. (MHUAF) Altman Z-score
Meihua International Medical Technologies Co., Ltd.'s Altman Z-score for fiscal 2025 is 2.00, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 2.00 | (0.53) |
| FY2024 | 2.52 | (0.69) |
| FY2023 | 3.21 | (3.84) |
| FY2022 | 7.05 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.65 | — | 0.78 | |
| Retained earnings / total assets | 0.54 | — | 0.76 | |
| EBIT / total assets | 0.04 | — | 0.13 | |
| Market value of equity / total liabilities | 0.04 | — | 0.03 | |
| Sales / total assets | 0.30 | — | 0.30 | |
| Altman Z-score | Grey zone | 2.00 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 17.18 | ||
Z and Z″ put Meihua International Medical Technologies Co., Ltd. in different zones: grey zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GCTK GlucoTrack, Inc. compare | 26,019,049× |
| NXGL NexGel, Inc. compare | 24.6× |
| MHUAF Meihua International Medical Technologies Co., Ltd. | 2.0× |
| RVP Retractable Technologies, Inc. compare | 0.6× |
| CUPR Cuprina Holdings (Cayman) Limited compare | −1.0× |
| LUCY Innovative Eyewear, Inc. compare | −3.7× |
| FEMY Femasys Inc. compare | −10.9× |
| BNGO Bionano Genomics, Inc. compare | −14.3× |
| RGNT Regentis Biomaterials Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets